Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2977 entries
Sorted by: Best Match Show Resources per page
Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis: I. Basic Principles, II. Preclinical Testing, and III. Clinical Testing.

Vaccines

Dannenberg AM, Dey B.
PMID: 26343850
Vaccines (Basel). 2013 Jan 25;1(1):58-76. doi: 10.3390/vaccines1010058.

Part I. Basic Principles. TB vaccines cannot prevent establishment of the infection. They can only prevent an early pulmonary tubercle from developing into clinical disease. A more effective new vaccine should optimize both cell-mediated immunity (CMI) and delayed-type hypersensitivity...

Cite
Dannenberg AM, Dey B. Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis: I. Basic Principles, II. Preclinical Testing, and III. Clinical Testing. Vaccines (Basel). 2013;1(1):58-76doi: 10.3390/vaccines1010058.
Dannenberg, A. M., & Dey, B. (2013). Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis: I. Basic Principles, II. Preclinical Testing, and III. Clinical Testing. Vaccines, 1(1), 58-76. https://doi.org/10.3390/vaccines1010058
Dannenberg, Arthur M, and Dey, Bappaditya. "Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis: I. Basic Principles, II. Preclinical Testing, and III. Clinical Testing." Vaccines vol. 1,1 (2013): 58-76. doi: https://doi.org/10.3390/vaccines1010058
Dannenberg AM, Dey B. Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis: I. Basic Principles, II. Preclinical Testing, and III. Clinical Testing. Vaccines (Basel). 2013 Jan 25;1(1):58-76. doi: 10.3390/vaccines1010058. PMID: 26343850; PMCID: PMC4552198.
Copy Download .nbib Format: NLM
Are Recent Medical Graduates More Skeptical of Vaccines?.

Vaccines

Mergler MJ, Omer SB, Pan WK, Navar-Boggan AM, Orenstein W, Marcuse EK, Taylor J, deHart MP, Carter TC, Damico A, Halsey N, Salmon DA.
PMID: 26343964
Vaccines (Basel). 2013 Apr 29;1(2):154-66. doi: 10.3390/vaccines1020154.

Rates of delay and refusal of recommended childhood vaccines are increasing in many U.S. communities. Children's health care providers have a strong influence on parents' knowledge, attitudes, and beliefs about vaccines. Provider attitudes towards immunizations vary and affect their...

Cite
Mergler MJ, Omer SB, Pan WK, et al. Are Recent Medical Graduates More Skeptical of Vaccines?. Vaccines (Basel). 2013;1(2):154-66doi: 10.3390/vaccines1020154.
Mergler, M. J., Omer, S. B., Pan, W. K., Navar-Boggan, A. M., Orenstein, W., Marcuse, E. K., Taylor, J., deHart, M. P., Carter, T. C., Damico, A., Halsey, N., & Salmon, D. A. (2013). Are Recent Medical Graduates More Skeptical of Vaccines?. Vaccines, 1(2), 154-66. https://doi.org/10.3390/vaccines1020154
Mergler, Michelle J, et al. "Are Recent Medical Graduates More Skeptical of Vaccines?." Vaccines vol. 1,2 (2013): 154-66. doi: https://doi.org/10.3390/vaccines1020154
Mergler MJ, Omer SB, Pan WK, Navar-Boggan AM, Orenstein W, Marcuse EK, Taylor J, deHart MP, Carter TC, Damico A, Halsey N, Salmon DA. Are Recent Medical Graduates More Skeptical of Vaccines?. Vaccines (Basel). 2013 Apr 29;1(2):154-66. doi: 10.3390/vaccines1020154. PMID: 26343964; PMCID: PMC4515582.
Copy Download .nbib Format: NLM
Hepatitis B Vaccination in Pregnancy in the United States.

Vaccines

Stewart RD, Sheffield JS.
PMID: 26343965
Vaccines (Basel). 2013 May 08;1(2):167-73. doi: 10.3390/vaccines1020167.

Hepatitis B remains a significant health issue worldwide, and contributes significantly to the incidence of cirrhosis and hepatocellular carcinoma. Widespread adoption of hepatitis B vaccination strategies has lead to significant declines in acute hepatitis B infections. Current recommendations for...

Cite
Stewart RD, Sheffield JS. Hepatitis B Vaccination in Pregnancy in the United States. Vaccines (Basel). 2013;1(2):167-73doi: 10.3390/vaccines1020167.
Stewart, R. D., & Sheffield, J. S. (2013). Hepatitis B Vaccination in Pregnancy in the United States. Vaccines, 1(2), 167-73. https://doi.org/10.3390/vaccines1020167
Stewart, Robert D, and Sheffield, Jeanne S. "Hepatitis B Vaccination in Pregnancy in the United States." Vaccines vol. 1,2 (2013): 167-73. doi: https://doi.org/10.3390/vaccines1020167
Stewart RD, Sheffield JS. Hepatitis B Vaccination in Pregnancy in the United States. Vaccines (Basel). 2013 May 08;1(2):167-73. doi: 10.3390/vaccines1020167. PMID: 26343965; PMCID: PMC4515586.
Copy Download .nbib Format: NLM
Vector Design for Improved DNA Vaccine Efficacy, Safety and Production.

Vaccines

Williams JA.
PMID: 26344110
Vaccines (Basel). 2013 Jun 25;1(3):225-49. doi: 10.3390/vaccines1030225.

DNA vaccination is a disruptive technology that offers the promise of a new rapidly deployed vaccination platform to treat human and animal disease with gene-based materials. Innovations such as electroporation, needle free jet delivery and lipid-based carriers increase transgene...

Cite
Williams JA. Vector Design for Improved DNA Vaccine Efficacy, Safety and Production. Vaccines (Basel). 2013;1(3):225-49doi: 10.3390/vaccines1030225.
Williams, J. A. (2013). Vector Design for Improved DNA Vaccine Efficacy, Safety and Production. Vaccines, 1(3), 225-49. https://doi.org/10.3390/vaccines1030225
Williams, James A. "Vector Design for Improved DNA Vaccine Efficacy, Safety and Production." Vaccines vol. 1,3 (2013): 225-49. doi: https://doi.org/10.3390/vaccines1030225
Williams JA. Vector Design for Improved DNA Vaccine Efficacy, Safety and Production. Vaccines (Basel). 2013 Jun 25;1(3):225-49. doi: 10.3390/vaccines1030225. PMID: 26344110; PMCID: PMC4494225.
Copy Download .nbib Format: NLM
Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques.

Vaccines

Borggren M, Vinner L, Andresen BS, Grevstad B, Repits J, Melchers M, Elvang TL, Sanders RW, Martinon F, Dereuddre-Bosquet N, Bowles EJ, Stewart-Jones G, Biswas P, Scarlatti G, Jansson M, Heyndrickx L, Grand RL, Fomsgaard A.
PMID: 26344115
Vaccines (Basel). 2013 Jul 19;1(3):305-27. doi: 10.3390/vaccines1030305.

HIV-1 DNA vaccines have many advantageous features. Evaluation of HIV-1 vaccine candidates often starts in small animal models before macaque and human trials. Here, we selected and optimized DNA vaccine candidates through systematic testing in rabbits for the induction...

Cite
Borggren M, Vinner L, Andresen BS, et al. Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques. Vaccines (Basel). 2013;1(3):305-27doi: 10.3390/vaccines1030305.
Borggren, M., Vinner, L., Andresen, B. S., Grevstad, B., Repits, J., Melchers, M., Elvang, T. L., Sanders, R. W., Martinon, F., Dereuddre-Bosquet, N., Bowles, E. J., Stewart-Jones, G., Biswas, P., Scarlatti, G., Jansson, M., Heyndrickx, L., Grand, R. L., & Fomsgaard, A. (2013). Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques. Vaccines, 1(3), 305-27. https://doi.org/10.3390/vaccines1030305
Borggren, Marie, et al. "Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques." Vaccines vol. 1,3 (2013): 305-27. doi: https://doi.org/10.3390/vaccines1030305
Borggren M, Vinner L, Andresen BS, Grevstad B, Repits J, Melchers M, Elvang TL, Sanders RW, Martinon F, Dereuddre-Bosquet N, Bowles EJ, Stewart-Jones G, Biswas P, Scarlatti G, Jansson M, Heyndrickx L, Grand RL, Fomsgaard A. Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques. Vaccines (Basel). 2013 Jul 19;1(3):305-27. doi: 10.3390/vaccines1030305. PMID: 26344115; PMCID: PMC4494233.
Copy Download .nbib Format: NLM
Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation.

Vaccines

Mendoza JM, Amante DH, Kichaev G, Knott CL, Kiosses WB, Smith TR, Sardesai NY, Broderick KE.
PMID: 26344120
Vaccines (Basel). 2013 Aug 28;1(3):384-97. doi: 10.3390/vaccines1030384.

The skin is an attractive tissue for vaccination in a clinical setting due to the accessibility of the target, the ease of monitoring and most importantly the immune competent nature of the dermal tissue. While skin electroporation offers an...

Cite
Mendoza JM, Amante DH, Kichaev G, et al. Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation. Vaccines (Basel). 2013;1(3):384-97doi: 10.3390/vaccines1030384.
Mendoza, J. M., Amante, D. H., Kichaev, G., Knott, C. L., Kiosses, W. B., Smith, T. R., Sardesai, N. Y., & Broderick, K. E. (2013). Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation. Vaccines, 1(3), 384-97. https://doi.org/10.3390/vaccines1030384
Mendoza, Janess M, et al. "Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation." Vaccines vol. 1,3 (2013): 384-97. doi: https://doi.org/10.3390/vaccines1030384
Mendoza JM, Amante DH, Kichaev G, Knott CL, Kiosses WB, Smith TR, Sardesai NY, Broderick KE. Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation. Vaccines (Basel). 2013 Aug 28;1(3):384-97. doi: 10.3390/vaccines1030384. PMID: 26344120; PMCID: PMC4494224.
Copy Download .nbib Format: NLM
Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.

Vaccines

Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E.
PMID: 26344888
Vaccines (Basel). 2014 Oct 13;2(4):707-34. doi: 10.3390/vaccines2040707.

Serological techniques commonly used to quantify influenza-specific antibodies include the Haemagglutination Inhibition (HI), Single Radial Haemolysis (SRH) and Virus Neutralization (VN) assays. HI and SRH are established and reproducible techniques, whereas VN is more demanding. Every new influenza vaccine...

Cite
Trombetta CM, Perini D, Mather S, et al. Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. Vaccines (Basel). 2014;2(4):707-34doi: 10.3390/vaccines2040707.
Trombetta, C. M., Perini, D., Mather, S., Temperton, N., & Montomoli, E. (2014). Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. Vaccines, 2(4), 707-34. https://doi.org/10.3390/vaccines2040707
Trombetta, Claudia Maria, et al. "Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future." Vaccines vol. 2,4 (2014): 707-34. doi: https://doi.org/10.3390/vaccines2040707
Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E. Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. Vaccines (Basel). 2014 Oct 13;2(4):707-34. doi: 10.3390/vaccines2040707. PMID: 26344888; PMCID: PMC4494249.
Copy Download .nbib Format: NLM
Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles.

Vaccines

McCullough KC, Milona P, Thomann-Harwood L, Démoulins T, Englezou P, Suter R, Ruggli N.
PMID: 26344889
Vaccines (Basel). 2014 Oct 16;2(4):735-54. doi: 10.3390/vaccines2040735.

Dendritic cells (DC) play essential roles determining efficacy of vaccine delivery with respect to immune defence development and regulation. This renders DCs important targets for vaccine delivery, particularly RNA vaccines. While delivery of interfering RNA oligonucleotides to the appropriate...

Cite
McCullough KC, Milona P, Thomann-Harwood L, et al. Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles. Vaccines (Basel). 2014;2(4):735-54doi: 10.3390/vaccines2040735.
McCullough, K. C., Milona, P., Thomann-Harwood, L., Démoulins, T., Englezou, P., Suter, R., & Ruggli, N. (2014). Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles. Vaccines, 2(4), 735-54. https://doi.org/10.3390/vaccines2040735
McCullough, Kenneth C, et al. "Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles." Vaccines vol. 2,4 (2014): 735-54. doi: https://doi.org/10.3390/vaccines2040735
McCullough KC, Milona P, Thomann-Harwood L, Démoulins T, Englezou P, Suter R, Ruggli N. Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles. Vaccines (Basel). 2014 Oct 16;2(4):735-54. doi: 10.3390/vaccines2040735. PMID: 26344889; PMCID: PMC4494254.
Copy Download .nbib Format: NLM
A Recombinant Raccoon Poxvirus Vaccine Expressing both Yersinia pestis F1 and Truncated V Antigens Protects Animals against Lethal Plague.

Vaccines

Rocke TE, Kingstad-Bakke B, Berlier W, Osorio JE.
PMID: 26344891
Vaccines (Basel). 2014 Oct 27;2(4):772-84. doi: 10.3390/vaccines2040772.

In previous studies, we demonstrated in mice and prairie dogs that simultaneous administration of two recombinant raccoon poxviruses (rRCN) expressing Yersinia pestis antigens (F1 and V307-a truncated version of the V protein) provided superior protection against plague challenge compared...

Cite
Rocke TE, Kingstad-Bakke B, Berlier W, et al. A Recombinant Raccoon Poxvirus Vaccine Expressing both Yersinia pestis F1 and Truncated V Antigens Protects Animals against Lethal Plague. Vaccines (Basel). 2014;2(4):772-84doi: 10.3390/vaccines2040772.
Rocke, T. E., Kingstad-Bakke, B., Berlier, W., & Osorio, J. E. (2014). A Recombinant Raccoon Poxvirus Vaccine Expressing both Yersinia pestis F1 and Truncated V Antigens Protects Animals against Lethal Plague. Vaccines, 2(4), 772-84. https://doi.org/10.3390/vaccines2040772
Rocke, Tonie E, et al. "A Recombinant Raccoon Poxvirus Vaccine Expressing both Yersinia pestis F1 and Truncated V Antigens Protects Animals against Lethal Plague." Vaccines vol. 2,4 (2014): 772-84. doi: https://doi.org/10.3390/vaccines2040772
Rocke TE, Kingstad-Bakke B, Berlier W, Osorio JE. A Recombinant Raccoon Poxvirus Vaccine Expressing both Yersinia pestis F1 and Truncated V Antigens Protects Animals against Lethal Plague. Vaccines (Basel). 2014 Oct 27;2(4):772-84. doi: 10.3390/vaccines2040772. PMID: 26344891; PMCID: PMC4494250.
Copy Download .nbib Format: NLM
Peptide Vaccines for Hypertension and Diabetes Mellitus.

Vaccines

Nakagami H, Koriyama H, Morishita R.
PMID: 26344893
Vaccines (Basel). 2014 Nov 26;2(4):832-40. doi: 10.3390/vaccines2040832.

Vaccines are commonly used as a preventive medicine for infectious diseases worldwide; however, the trial for an amyloid beta vaccine against Alzheimer's disease will open a new concept in vaccination. In case of therapeutic vaccines for cancer, their targets...

Cite
Nakagami H, Koriyama H, Morishita R. Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines (Basel). 2014;2(4):832-40doi: 10.3390/vaccines2040832.
Nakagami, H., Koriyama, H., & Morishita, R. (2014). Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines, 2(4), 832-40. https://doi.org/10.3390/vaccines2040832
Nakagami, Hironori, et al. "Peptide Vaccines for Hypertension and Diabetes Mellitus." Vaccines vol. 2,4 (2014): 832-40. doi: https://doi.org/10.3390/vaccines2040832
Nakagami H, Koriyama H, Morishita R. Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines (Basel). 2014 Nov 26;2(4):832-40. doi: 10.3390/vaccines2040832. PMID: 26344893; PMCID: PMC4494253.
Copy Download .nbib Format: NLM
Micelle-Based Adjuvants for Subunit Vaccine Delivery.

Vaccines

Trimaille T, Verrier B.
PMID: 26426060
Vaccines (Basel). 2015 Sep 25;3(4):803-13. doi: 10.3390/vaccines3040803.

In the development of subunit vaccines with purified or recombinant antigens for cancer and infectious diseases, the design of improved and safe adjuvants able to efficiently target the antigen presenting cells, such as dendritic cells, represents a crucial challenge....

Cite
Trimaille T, Verrier B. Micelle-Based Adjuvants for Subunit Vaccine Delivery. Vaccines (Basel). 2015;3(4):803-13doi: 10.3390/vaccines3040803.
Trimaille, T., & Verrier, B. (2015). Micelle-Based Adjuvants for Subunit Vaccine Delivery. Vaccines, 3(4), 803-13. https://doi.org/10.3390/vaccines3040803
Trimaille, Thomas, and Verrier, Bernard. "Micelle-Based Adjuvants for Subunit Vaccine Delivery." Vaccines vol. 3,4 (2015): 803-13. doi: https://doi.org/10.3390/vaccines3040803
Trimaille T, Verrier B. Micelle-Based Adjuvants for Subunit Vaccine Delivery. Vaccines (Basel). 2015 Sep 25;3(4):803-13. doi: 10.3390/vaccines3040803. PMID: 26426060; PMCID: PMC4693219.
Copy Download .nbib Format: NLM
Emerging Vaccine Technologies.

Vaccines

Loomis RJ, Johnson PR.
PMID: 26343196
Vaccines (Basel). 2015 May 26;3(2):429-47. doi: 10.3390/vaccines3020429.

Vaccination has proven to be an invaluable means of preventing infectious diseases by reducing both incidence of disease and mortality. However, vaccines have not been effectively developed for many diseases including HIV-1, hepatitis C virus (HCV), tuberculosis and malaria,...

Cite
Loomis RJ, Johnson PR. Emerging Vaccine Technologies. Vaccines (Basel). 2015;3(2):429-47doi: 10.3390/vaccines3020429.
Loomis, R. J., & Johnson, P. R. (2015). Emerging Vaccine Technologies. Vaccines, 3(2), 429-47. https://doi.org/10.3390/vaccines3020429
Loomis, Rebecca J, and Johnson, Philip R. "Emerging Vaccine Technologies." Vaccines vol. 3,2 (2015): 429-47. doi: https://doi.org/10.3390/vaccines3020429
Loomis RJ, Johnson PR. Emerging Vaccine Technologies. Vaccines (Basel). 2015 May 26;3(2):429-47. doi: 10.3390/vaccines3020429. PMID: 26343196; PMCID: PMC4494353.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2977 entries